Jane Huang Prelude Therapeutics Inc (PRLD) insider trading activity

Jane Huang is President, CMO of Prelude Therapeutics Inc. Currently has a direct ownership of 86,917 shares of PRLD, which is worth approximately $132,983. The most recent transaction as insider was on Oct 04, 2025, when has been sold 3,355 shares (Common Stock) at a price of $1.47 per share, resulting in proceeds of $4,931. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 86.9K

7.44% 3M change

37.22% 12M change

Total Value Held $132,983

Jane Huang Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Oct 04 2025	SELL Payment of exercise price or tax liability	$4,931 $1.47 p/Share	3,355 Reduced 3.72%	86,917 Common Stock
Oct 04 2025	BUY Exercise of conversion of derivative security	-	9,375 Added 9.41%	90,272 Common Stock
Jul 04 2025	SELL Payment of exercise price or tax liability	$2,650 $0.79 p/Share	3,355 Reduced 3.98%	80,897 Common Stock
Jul 04 2025	BUY Exercise of conversion of derivative security	-	9,375 Added 10.01%	84,252 Common Stock
Apr 04 2025	SELL Payment of exercise price or tax liability	$2,281 $0.68 p/Share	3,355 Reduced 4.29%	74,877 Common Stock
Apr 04 2025	BUY Exercise of conversion of derivative security	-	9,375 Added 10.7%	78,232 Common Stock
Jan 04 2025	SELL Payment of exercise price or tax liability	$5,364 $1.39 p/Share	3,859 Reduced 5.31%	68,857 Common Stock

Jan 04 2025	BUY Exercise of conversion of derivative security	-	9,375 Added 11.42%	72,716 Common Stock
Oct 04 2024	SELL Payment of exercise price or tax liability	$6,698 $2.0 p/Share	3,349 Reduced 5.02%	63,341 Common Stock
Oct 04 2024	BUY Exercise of conversion of derivative security	-	9,375 Added 12.32%	66,690 Common Stock
Jul 04 2024	SELL Payment of exercise price or tax liability	$12,049 $3.6 p/Share	3,347 Reduced 5.52%	57,315 Common Stock
Jul 04 2024	BUY Exercise of conversion of derivative security	-	9,375 Added 13.39%	60,662 Common Stock
Apr 04 2024	SELL Payment of exercise price or tax liability	$15,864 $4.74 p/Share	3,347 Reduced 6.13%	51,287 Common Stock
Apr 04 2024	BUY Exercise of conversion of derivative security	-	9,375 Added 14.65%	54,634 Common Stock
Jan 04 2024	SELL Payment of exercise price or tax liability	$14,491 $3.77 p/Share	3,844 Reduced 7.83%	45,259 Common Stock
Jan 04 2024	BUY Exercise of conversion of derivative security	-	9,375 Added 16.03%	49,103 Common Stock
Oct 04 2023	BUY Exercise of conversion of derivative security	-	9,375 Added 19.09%	39,728 Common Stock
Jul 04 2023	SELL Payment of exercise price or tax liability	$15,075 $4.65 p/Share	3,242 Reduced 9.65%	30,353 Common Stock
Jul 04 2023	BUY Exercise of conversion of derivative security	-	9,375 Added 21.82%	33,595 Common Stock
Apr 06 2023	SELL Open market or private sale	$81,273 $6.12 p/Share	13,280 Reduced 35.41%	24,220 Common Stock
Apr 04 2023	BUY Exercise of conversion of derivative security	-	37,500 Added 50.0%	37,500 Common Stock

Also insider at

BGNE

BeiGene, Ltd. Healthcare

CMO, Hematology

TARA

Protara Therapeutics, Inc. Healthcare

Jane Huang

President, CMO

Camana Bay, Grand Cayman, E9

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells PRLD shares.

Notify only if

Value

Insider Trading

Get notified when an Prelude Therapeutics Inc insider buys or sells PRLD shares.

Notify only if

Operation

Value

Type

News

Receive news related to Prelude Therapeutics Inc

Track Activities on PRLD

Account